Featured Articles
CONTROLLED RELEASE - Informed Selection of Modified-Release Technologies Provides Simpler Oral Dose Regimens
Ronak Savla, PhD, reviews some of the physicochemical and biopharmaceutical characteristics of drugs and how they influence creation of a controlled drug delivery formulation.
DRUG DEVELOPMENT - Cell & Gene Therapies Calling for Innovation in Drug Development
Lev Gerlovin and Pascale Diesel, PharmD, believe there is significant evidence to indicate that we are entering a golden age of gene and cell therapy development, and while industry works to advance these programs, the debate over new approaches in both structuring and financing clinical research is likely to continue.
LIPID-BASED DELIVERY - Advanced Lipid-Based Drug Delivery Systems: Solid Lipid Nanoparticles & Nanostructured Lipid Carriers
John K. Tillotson, RPh, PhD, believes increased research and development of these drug delivery platforms will continue to advance therapeutic efficacy and safety for emerging difficult-to-deliver actives.
HIGH-RESOLUTION MASS SPECTROMETRY - A Map to Biologics
William Boomershine, PhD, explains how high-resolution mass spectrometry is a key component to the characterization of novel biologics and biosimilars.
EXECUTIVE INTERVIEW - SHL Group: Expansion Driven by Our Partners
Taras Seniuch, Director of Business Development at SHL’s contract manufacturing organization, SHL Pharma, talks about his company’s unique service offering for its partners.
DRUG DELIVERY - Targeted Delivery of Submicron Particle Cancer Chemotherapy: Helping Shift the Immunotherapy Paradigm
Marc A. Iacobucci says that with much attention and research investment into IOT, NanOlogy is shaping a new paradigm for cancer treatment by attempting to improve the safety and effectiveness of tried and true CT through local delivery.
Nkarta Therapeutics Announces Exclusive License to Natural Killer Cell Technology
Nkarta Therapeutics recently announced it has entered into a worldwide exclusive license agreement for proprietary Natural Killer cell engineering technology jointly owned by the National…
SPECIAL FEATURE - Outsourcing Formulation Development & Manufacturing: CDMOs Are Innovating for 21st-Century Medicine
Contributor Cindy H. Dubin speaks with some of the industry’s leading CDMOs about the innovations they are developing for next-generation patient care, and how many are making investments that are enabling them to offer more services under one roof.
GLOBAL REPORT - 2017 Global Drug Delivery & Formulation Report: Part 4, The Drug Delivery & Formulation Pipeline
In the final installment of this 4-part series, PharmaCircle in collaboration with Drug Development & Delivery, provides a pipeline review and analysis (centered on drug delivery and formulation products) looking forward and back 5 years for a total of 10 years.
ANTIBODY DISCOVERY - Why Understanding Immune Dysregulation is the Key to Drug Development
David S. Johnson, PhD, provides a unique insight into immune dysregulation through a proprietary technology known as Surge – a platform that quickly characterizes every cell in complex immune systems so that natural immune repertoires can be translated into medical treatments.
PEPTIDE DELIVERY - The Endometriosis Enigma – Why Can't There Be a Pill for That?
Joel Tune, MBA, says for those peptide therapeutics that meet the necessary criteria, advances in formulation technologies coupled with favorable market dynamics will continue to drive interest across the entire prescription drug spectrum for safe and effective orally administered peptide therapeutics.
MICROFLUIDICS - Taking a Microfluidics Approach to Drug Delivery
Richard Gray, MA, and Pavel Abdulkin, PhD, look at how microfluidics is changing the drug development sector and explore an exciting new non-encapsulating microparticle-based approach that offers “tunable” release of the API.
PERSONALIZED IMMUNOTHERAPY - Off-the-Shelf Personalized Immunotherapy for Breast Cancer: The BriaCell Solution
William V. Williams, MD, Markus Lacher, PhD, and Charles L. Wiseman, MD, explain how there is a clear need for ways to stimulate effective cancer-specific immune responses while avoiding time-consuming and costly individualized manufacturing.
THERAPEUTIC FOCUS - Antisense Drug Shown to Significantly Reduce Triglyceride Levels in Patients With Severe Hypertriglyceridemia
Ioanna Gouni-Berthold, MD, provides results from a clinical study indicating antisense technology can result in significant reductions in triglyceride levels in patients with hypertriglyceridemia.
MULTIPARTICULATE SYSTEM - Advances in Lipid Multiparticulate Technologies for Controlled Release
Jaspreet Arora, PhD, Samantha Saville, and Brett Waybrant, PhD, focus on a controlled-release LMP formulation to identify optimum annealing conditions and to better understand the annealing mechanism.
CLINICAL TRIALS - Maximizing Immuno-Oncology Clinical Trial Success
Luke S. Gill, MSc, MBA, believes understanding and overcoming various challenges in the development of immunotherapeutic agents will be critical to clinical trial success and, ultimately, market approval.
SPECIAL FEATURE - Prefilled Syringes & Parenteral Manufacturing: Drug & Packaging Ensure Safety, Compatibility & Stability
Contributor Cindy H. Dubin highlights some of the key players in the market and where they are focusing their efforts to ensure products are of the highest quality, safe, and easy to use.
EXECUTIVE INTERVIEW - Singota Solutions: Keeping Up With Trends & Technology as a CDMO
Brent Lieffers, Senior Director of Operations, discusses the need for keeping up with trends and technology as an innovative CDMO.
GLOBAL REPORT - 2017 Global Drug Delivery & Formulation Report: Part 3, Notable Transactions & Technologies of 2017
In part 3 of this 4-part series, PharmaCircle in collaboration with Drug Development & Delivery, reviews transactions and technologies that provide greater insight into what we can expect in terms of product development and approvals over the next decade.
SOLID FORM SCREENING - Phase Appropriate Strategies for Solid Form Discovery & Development
Pingyun Chen, PhD, describes a rational, fit-for-purpose strategy for solid form screening and selection to ensure a successful yet cost-effective progression of drug candidates from discovery, clinical trials, and commercialization.
